Call Now: +1 858 800 3101 Email: info@innopep.com
Shopping Cart
0 Item(s) - $0.00
Your shopping cart is empty!
VEGFR2/KDR Antagonist
| Overview | |
|---|---|
| Description | This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo. |
| Sequence | ATWLPPR |
| Sequence (3 Letter) | H-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH |
| Molecular Weight | 840 |
| Properties | |
| Purity | > 95% By HPLC |
| Storage | Store at -20 °C, cap vial tightly at all times. |
Ref: Renno, R. et al. Invest. Ophthalmol. Vis. Sci. 43, 3977 (2002); Brekken, R. et al. Cancer Res. 60, 5117 (2000); Jia, H. et al. J. Biol. Chem. 279, 36148 (2004); Ye, F. Gynecol. Oncol. 94, 125 (2004); Bin?truy-Tournaire, R. et al. EMBO J. 19, 1525 (2000).
About InnoPep
InnoPep Inc. is a company started by a couple of researchers with decades of expertise in peptide synthesis and conjugation aimed at enabling.